Skip to main content

Table 2 comparison of composite unfavorable outcome (primary outcome) and successful TB treatment (secondary outcome) between Nevirapine and Efavirenz

From: Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study

 

Center 1

Center 2

Combined data

Nevirapine (n = 67) (%)

Efavirenz (n = 74) (%)

Effect size (95% CI)

Nevirapine (n = 77) (%)

Efavirenz (n = 66) (%)

Effect size (95% CI)

Nevirapine (n = 144) (%)

Efavirenz (n = 140) (%)

Effect size (95% CI)

Composite unfavorable outcome

Unadjusted

30 (44.8%)

29 (39.2%)

5.6% (−10.7,21.9)

19 (24.7%)

22 (33.3%)

−8.7% (−23.6,6.2)

49 (34%)

51 (36.4%)

−2.4% (−13.5,8.7)

Adjusted for stage

44.1%

39.7%

−7.8% (−33.3,7.7)

26.2%

34.8%

4% (−6.4,14.5)

35.3%

36.9%

4.5% (−5.1,14)

ART failure

Unadjusted

20 (29.9%)

22 (29.7%)

1.2% (−15,15)

19 (24.7%)

20 (30.3%)

−5.6% (−20.7,9.1)

40 (27.8%)

43 (30.7%)

−2.9% (−13.5,8.7)

Adjusted for stage

29.5%

30%

−4.3% (−28,19.5)

27.5%

33.2%

2.8% (−7.7,13.3)

28.7%

31.3%

13.2% (−7.8,10.5)

Death

Unadjusted

13 (19.4%)

10 (13.5%)

5.9% (−6.4,18.2)

6 (7.8%)

7 (10.6%)

−2.8% (−12.4,6.7)

19 (13.2%)

17 (12.1%)

1.1% (−6.7,8.8)

Adjusted for stage

18.4%

14.4%

−11.7% (−30.7,7.3)

8.2%

11.1%

0.05% (−6.7,6.8)

13.6%

12.4%

−0.2 (−6.9,6.4)

Successful TB treatment at 48 weeks

Unadjusted

39 (58.2%)

39 (52.7%)

5.5% (−10.9,22)

63 (81.8%)

51 (77.3%)

4.5% (−7.6,18.8)

102 (71.3%)

90 (64.3%)

7% (−3.8,17.9)

Adjusted for stage

59.4%

51.6%

15.2% (−10.4,40.8)

84.6%

79.5%

−4.1% (−12.8,4.7)

71.5%

65.6%

−7% (−16.2,2.2)